These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. Ni X; Zhang C; Talpur R; Duvic M J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832 [TBL] [Abstract][Full Text] [Related]
65. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). Wong HK G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210 [TBL] [Abstract][Full Text] [Related]
66. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome. Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733 [TBL] [Abstract][Full Text] [Related]
67. Mycosis Fungoides and Sezary Syndrome. Foss FM; Girardi M Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880 [TBL] [Abstract][Full Text] [Related]
68. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755 [TBL] [Abstract][Full Text] [Related]
69. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter. Choi MY; Lechowicz MJ Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949 [TBL] [Abstract][Full Text] [Related]
70. Delving into the Metabolism of Sézary Cells: A Brief Review. Cherfan C; Chebly A; Rezvani HR; Beylot-Barry M; Chevret E Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790264 [TBL] [Abstract][Full Text] [Related]
71. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856 [TBL] [Abstract][Full Text] [Related]
73. A modified staging classification for cutaneous T-cell lymphoma. Kashani-Sabet M; McMillan A; Zackheim HS J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919 [TBL] [Abstract][Full Text] [Related]
74. Chromosomally clonal T cells in the skin, blood, or lymph nodes of two Sezary syndrome patients express CD45RA, CD45RO, CDw150, and interleukin-4, but no interleukin-2 or interferon-gamma. Karenko L; Nevala H; Raatikainen M; Franssila K; Ranki A J Invest Dermatol; 2001 Jan; 116(1):188-93. PubMed ID: 11168816 [TBL] [Abstract][Full Text] [Related]
75. NOTCH1 signaling as a therapeutic target in Sézary syndrome. van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117 [TBL] [Abstract][Full Text] [Related]